This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Palatin Technologies Presents Positive New Data Analyses Demonstrating Efficacy Of Bremelanotide In Female Hypoactive Sexual Desire Disorder

CRANBURY, N.J., Feb. 24, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined HSDD/female sexual arousal disorder (FSAD), both which are forms of female sexual dysfunction (FSD). 1,2,3

The data from three clinical abstracts were presented Saturday, February 22, 2014 at the International Society for the Study of Women's Sexual Health (ISSWSH) conference in San Diego.  Bremelanotide is a first-in-class, investigative melanocortin agonist being developed for treatment of female sexual dysfunction (FSD).

"We are excited by the potential that bremelanotide may offer women in treating HSDD, a condition that has been recognized for more than 30 years but for which there is no FDA-approved therapy," said Carl Spana, Ph.D., President and CEO of Palatin. "Unlike other investigational therapies in development for FSD, bremelanotide is an on-demand medication that has been shown to work within 30 to 60 minutes of administration. That would allow women to take it when they need it, providing them with a quick response, greater control and flexibility in their treatment." 

In one abstract, responder analyses showed bremelanotide had a statistically significant increase in the percentage of women whose total score on the Female Sexual Function Index (FSFI) – a measure of overall sexual functioning – improved: 69% for 1.75 mg versus 46% for placebo (p<0.05). 1 In addition, a significantly higher percentage of women on bremelanotide versus placebo achieved at least one satisfying sexual event (SSE): 55% for 1.75 mg versus 37% for placebo (p<0.05). 1 

A second abstract, presenting data from the episodic questionnaire, Female Sexual Encounter Profile – Revised (FSEP-R), demonstrated greater mean increases in SSEs within 24 hours of dosing with bremelanotide 1.75 mg (mean increase: 0.7; p=0.0443) versus placebo (mean increase: 0.1).  As-needed administration of bremelanotide 1.75 mg versus placebo also demonstrated episodic increases in levels of desire (0.4 vs. 0.0, respectively) and in the women's satisfaction with their levels of desire (0.6 vs. 0.1, respectively). 2

In a third abstract, data collected from the Women's Inventory of Treatment Satisfaction (WITS-9) showed women who completed treatment were significantly more satisfied with bremelanotide 1.75 mg (0.77; p=0.0204) versus placebo (0.17). 3

"Additional analyses continue to yield robust, positive data for bremelanotide, which shows promise in addressing an important unmet need for women living with HSDD," said David J. Portman, MD, Principal Investigator at the Columbus Center for Women's Health Research, and in private practice with Portman Obstetrics and Gynecology. "The findings from these abstracts show that bremelanotide can significantly improve desire and sexual functioning.  More importantly, women were satisfied with treatment, which is a predictor not just of satisfaction but with compliance and the continuation of treatment."

Bremelanotide was well-tolerated during the trial. The most common types of treatment-emergent adverse events reported more frequently in the bremelanotide arms were facial flushing, nausea and emesis, which were mainly mild-to-moderate in severity. The study dosed 394 patients. Adverse events that most commonly led to discontinuation were nausea and emesis. No serious adverse events were attributed to bremelanotide during the trial.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%
YHOO $36.60 0.03%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs